Byetta Associated with Fatal Pancreatitis
Byetta (exenatide), an injectable type 2 diabetes drug marketed by Amylin Pharmaceuticals, Inc. and Eli Lilly & Company, was approved by the FDA in 2005 as an adjunct to diet and exercise to improve glycemic control. Byetta is not used for treatment of patients with type 1 diabetes. The FDA issued its first warning in 2007 about Byetta being associated with acute pancreatitis.
In 2008 the FDA warned that it had received additional reports about fatal and non-fatal hemorrhagic pancreatitis (inflammation of the pancreas with bleeding) or necrotizing (severe) pancreatitis in patients using Byetta. In August 2008, after more deaths and more than thirty people hospitalized, the FDA ordered the warning label Byetta strengthened.
If you or a loved one suffered from pancreatitis while using Byetta contact the Plymale Law Firm for a free consultation by filling out the form on this page or by calling (877) 328-7670.